Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed metastatic, recurrent, or refractory
epithelial endometrial carcinoma Must be one of the following histologic types:
Endometrioid adenocarcinoma Villoglandular Secretory Ciliated Endometrioid adenocarcinoma
with squamous differentiation Serous carcinoma Clear cell carcinoma Mucinous carcinoma
Squamous carcinoma Mixed types of carcinoma Undifferentiated carcinoma Must not be
amenable to surgery or radiotherapy Documented evidence of progression at site if the only
site of measurable disease has been irradiated Metastatic sites need not be biopsied
Measurable disease

PATIENT CHARACTERISTICS: Age: 16 and over Performance status: SWOG 0-2 Life expectancy:
Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal
(ULN) SGOT no greater than 2 times ULN Renal: Creatinine no greater than 2.0 mg/dL
Creatinine clearance at least 25 mL/min Other: At least 5 years since other prior
malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in
situ of the cervix, or adequately treated stage I or II cancer in complete remission Not
pregnant or nursing Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy No more than 1
prior biologic therapy regimen Chemotherapy: No concurrent chemotherapy No prior taxane
for any reason No more than 2 prior chemotherapy courses used for the sole purpose of
radiosensitization during primary definitive therapy allowed No other prior chemotherapy
Endocrine therapy: No concurrent hormonal therapy Prior hormonal or other endocrine
therapy allowed Radiotherapy: No concurrent radiotherapy except to sites of bone
metastases for palliative control of pain Prior radiotherapy to no more than 30% of bone
marrow allowed At least 4 weeks since radiotherapy and recovered Surgery: Prior surgery
allowed Must have recovered from surgery and any complication therefrom